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Background: Platelet to lymphocyte ratio (PLR) is a prognostic factor for various tumors, but the current opinion
on the prognostic value of PLR in liver transplantation (LT) for hepatocellular carcinoma (HCC) is still controversial.
The aim of this study was to investigate the value of pre-transplant PLR for predicting post-LT HCC recurrence and
further evaluate the correlation of PLR with tumor-related characteristics.
Methods: The clinical data of 343 LT for HCC was retrospectively analyzed. The receiver operating characteristic
(ROC) curve was used to determine the optimal PLR cut-off value to predict HCC recurrence after LT. The tumor-free
survival rates were compared between high and low PLR groups divided by different pre-transplant PLR cut-off values.
The relationship of elevated PLR and tumor-related characteristics were also analyzed. Additionally, the tumor-free
survival was compared according to different platelet and lymphocyte counts.
Results: PLR 125 was the most significant cut-off value in predicting tumor-free survival after LT, with the sensitivity
and specificity of 61.6% and 62.7%, respectively. PLR ≥125 was associated with significantly higher proportion of
multiple tumors, large tumor size, and micro- and macro-vascular invasion than PLR <125. Of patient with
PLR <125, 46.9%, 54.2%, and 61.5% were within Milan, UCSF, and Hangzhou criteria, respectively, significantly
higher than 16.4%, 18.2%, and 29.1% in the PLR ≥125 group, respectively. There was no relationship between
tumor-free survival and platelet or lymphocyte count independently.
Conclusions: Pre-transplant PLR ≥125 was associated with advanced tumor stage and aggressive tumor
behavior, and it can be used as a prognostic factor for post-transplant HCC recurrence.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide and the third cause of tumor-
related death [1]. Liver transplantation (LT) is an ideal
option for well-selected HCC patients because this treat-
ment completely removes not only the tumor but also
the underlying cirrhotic liver disease [2]. In 1996, the* Correspondence: shusenzheng@zju.edu.cn
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unless otherwise stated.Milan criteria was introduced to optimize the clinical
outcome of HCC patients after LT, but it has been
proven to be too strict; a large proportion of patients
with HCC beyond Milan criteria also have a substantial
curative chance after LT. Thereafter, several expanded
criteria were introduced in clinical practice [3-6]. The
University of California San Francisco (UCSF) criteria
and Hangzhou criteria were presented by Yao et al. in
2001 [5] and by Zheng et al. in 2008 [6], respectively.
Most of current selection criteria are based on tumor
number, tumor size, and macro-vascular invasion which
are evaluated by pre-transplant radiological imaging.
However, the accuracy of radiological imaging is unsatis-
factory, even unacceptable [7]. On the other hand, thes is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ation and micro-vascular invasion cannot be evaluated
by radiological imaging, and these two factors are
strongly associated with an increased risk of tumor re-
currence after LT [8-10]. This situation prompts us to
identify other predictors of HCC recurrence after LT.
Recently, systemic inflammation is proven to be
related to poor prognosis and increased tumor progres-
sion. The tumor can upregulate the inflammatory
process, and the inflammatory cells can release cytokines
and mediators to promote angiogenesis, tumor prolifera-
tion, and metastasis [11,12]. The platelet to lymphocyte
ratio (PLR) has been used as a marker to evaluate the
systemic inflammatory responses, and PLR is shown to
be a prognostic factor in various tumors [13-15]. For
HCC, conflicting data exist regarding the ability of PLR
of predicting prognosis of HCC patients. Lai et al. dem-
onstrate that PLR is a good predictor for the risk of
post-LT recurrence [16], but other studies fail to find
correlation between PLR and clinical outcome of HCC
patients [17,18]. To date, the current opinion on the
prognostic role of PLR in LT for HCC is still controver-
sial. We therefore conducted this study to investigate
the predictive value of PLR for post-transplant tumor
recurrence.Methods
Patients
A total of 343 patients who received LT for HCC were
enrolled in this retrospective study, and all the HCC
developed in the background of liver cirrhosis which
was confirmed by pathology of explant liver. The ex-
clude criteria were (1) recipient age less than 18 years,
(2) patients who died during the first month after LT, (3)
recipients without adequate blood records and clinical
data, and (4) patients with pre-transplant sepsis, hypers-
plenism, or massive gastrointestinal tract bleeding. All
the LT were performed in the first affiliated hospital,
School of Medicine, Zhejiang University, between January
2003 and December 2013.
Ethical approval was obtained from the Committee of
Ethics in Biomedical Research of Zhejiang University and
conformed to the ethical guidelines of the Declaration of
Helsinki. Written informed consents were obtained from
all participants.Study design and data collection
The blood cell testing is performed every week or neces-
sary before LT; the PLR was calculated as the ratio of
platelet count to lymphocyte count according to the
blood cell testing performed within 1 month before LT;
if more than one set of measurement were available for
a given patient, only the minimal PLR value was used.The HCC patients were divided into high PLR and low
PLR groups according to the pre-transplant PLR values.
The definite diagnosis of HCC and the tumor-related
characteristics including tumor number, tumor size, macro-
vascular invasion, micro-vascular invasion, and tumor cell
differentiation grading were judged based on pathological
findings. The judgment of histological fulfillment of Milan
criteria [2], UCSF criteria [5], or Hangzhou criteria [6] for
a given patients was based on pathological examination of
explant livers.
The recipients’ clinical variables including age, gender,
model of end-stage liver disease (MELD) score, hepatitis
B virus (HBV) infection status, and transplantation type
(living donor liver transplantation [LDLT] or deceased
donor liver transplantation [DDLT]) were collected and
evaluated. The pre-transplant treatments of HCC were
also recorded: surgical resection and interventional ther-
apies including transarterial chemoembolization (TACE),
radiofrequency ablation (RFA), and percutaneous etha-
nol injection (PEI).Follow-up
All transplanted recipients were followed up; the mean
follow-up period was 33.7 months, ranged from 9.5 to
132.0 months. Screening for tumor recurrence was per-
formed by α fetoprotein (AFP) measurement and ultra-
sonography every month during the first 6 months and
performed every 2 months during the second 6 months.
In the following years, the patients received examinations
every 3 to 6 months or when necessary. Plain/enhanced
thoracoabdominal computed tomography was performed
every 6 months or when necessary. Bone scan or positron
emission tomography was carried out in case of suspected
HCC recurrence.Statistical analysis
Data were summarized using mean with standard devi-
ation (SD) for continuous variables and percentage for
discrete variables. Student’s t tests and Mann–Whitney
U test were used for comparison of continuous with
normal distribution and nonparametric distribution, re-
spectively. Chi-square test was used for categorical vari-
ables. Survival analysis was performed using the Kaplan-
Meier methods and compared using the log-rank test.
Receiver operating characteristic (ROC) analysis was
used to determine the PLR cut-off value with most sig-
nificance in predicting tumor recurrence after LT; the
optimal PLR cut-off value was considered when highest
Youden index (sensitivity + specificity-1) was presented.
Data were analyzed using SPSS 16.0 (SPSS Inc. Chicago,
CA, USA). The P value <0.05 was considered statistically
significant.
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Clinical characteristics of 343 patients received LT for HCC
A total of 343 HCC patients including 308 (89.8%) males
and 35 (10.2%) females were enrolled in this study; their
mean age was 49.4 (from 19.0 to 71.0) years; the calcu-
lated MELD score before transplantation was 13.0 ± 6.0,
320 (93.3%) were HBV infected, 41 (12.0%) patients re-
ceived LDLT, and 302 (88.0%) received DDLT. The mean
follow-up period was 33.7 months, ranged from 9.5 to
132.0 months.
Of these patients, 144 (42.0%) patients fulfilled the
Milan criteria; 166 (48.4%) and 193 (56.3%) patients
were within the UCSF and Hangzhou criteria, respect-
ively. Before LT, 52 (15.2%) patients received surgical
tumor resections and 170 (49.6%) received interventional
therapies.
Tumor-free survival of patients according to different PLR
cut-off values
The PLR cut-off values varied among different studies
ranging from 100 to 300; some studies used PLR 160 or
less, while others used more than 160 [19]. As the first
step, we used the ROC curve to determine the PLR cut-
off value with the most significance in predicting HCC
recurrence after LT. The area under ROC curve was
0.627, and the Youden index was highest when the PLR
was 125; the sensitivity and specificity were 61.6% and
62.7%, respectively. Therefore, we considered PLR = 125
as the optimal cut-off (Figure 1). The 1-, 3-, and 5-year
tumor-free survival rates were 66.8%, 54.6%, and 53.1%
in PLR <125 patients, respectively, significantly higher
than 39.9%, 29.8%, and 29.8% in PLR ≥125 patients,Figure 1 ROC curve for the PLR values to predict HCC recurrence
after LT. The area under ROC curve was 0.627. The PLR value 125 was
considered as the optimal cut-off value because of its highest Youden
index; the sensitivity and specificity were 61.6% and 62.7%, respectively.respectively (Figure 2A). We further compared the over-
all patient survival rates between PLR ≥125 and <125 pa-
tients; of patients with PLR <125, the 1-, 3-, and 5-year
overall patient survival rates were 81.0%, 63.6%, and
56.7%, respectively, significantly better than 67.3%,
45.0%, and 40.5% of patients in PLR ≥125 group, re-
spectively (P = 0.012, Figure 2B).
In addition, because various PLR cut-off values were
used in previous studies, we also compared the tumor-
free survival rates according to different values. We
found that significant differences were presented when
PLR cut-off values of 100, 125, and 150 were used
(Table 1). Of these, the cut-off value of 125 was the most
significant (P = 0.000). In the next analysis, we used the
PLR 125 as the cut-off value.
Comparison of recipients’ clinical characteristics between
PLR ≥125 and PLR <125 groups
Patients with PLR <125 showed better prognosis than
that with PLR ≥125; the clinical backgrounds of recipi-
ents in two groups were then compared. As shown in
Table 2, between PLR <125 and ≥125 groups, the clin-
ical variables including age, gender, MELD score, HBV
infection status, and transplantation type were com-
parable, and the pre-transplant HCC treatments in-
cluding surgical resection and interventional therapies
were also similar. This result indicated that the clinical
characteristics of recipients in two groups were
comparable.
Influences of tumor-related characteristics on tumor-free
survival
We next examined that whether the different tumor re-
currence was caused by disparity of tumor-related char-
acteristics (tumor number, largest and total tumor size,
macro- and micro-vascular invasion, tumor differenti-
ation, pre-transplant AFP level and fulfill of Milan,
UCSF, or Hangzhou criteria) between two groups or not.
We analyzed the influences of tumor-related characteris-
tics on tumor-free survival rates. As shown in Table 3,
all of the tumor-related characteristics examined in this
study were proven to be predictive for tumor-free sur-
vival after LT.
Relationship between PLR value and tumor-related
characteristics
We then evaluated the distribution of tumor-related
characteristics in PLR ≥125 and <125 groups. We found
that patients with PLR ≥125 displayed high proportion
of multiple tumors, large tumor size, and micro- and
macro-vascular invasion, but there was no difference be-
tween two groups in terms of tumor differentiation and
AFP levels. For histological fulfillment of selection cri-
teria, 46.9%, 54.2%, and 61.5% patients with PLR <125
Figure 2 Comparison of tumor-free survival and overall patient survival between PLR ≥125 and <125 patients. The patients were divided
into two groups according to the pre-transplant PLR cut-off value of 125. Recipients with PLR <125 presented significantly higher tumor-free
survival rates (P = 0.000, (A)) and overall patient survival rates (P = 0.012, (B)) than that with PLR ≥125.
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spectively, significantly higher than 16.4%, 18.2%, and
29.1% in PLR ≥125 group, respectively (Table 4). This re-
sult indicated that patients with PLR ≥125 tended to be
associated with multiple tumors, large tumor size, and
micro- and macro-vascular invasion, and this disparity
maybe the explanation of the poor prognosis of patients
with PLR ≥125.Comparison of HCC recurrence according to platelet and
lymphocyte counts
About the molecular mechanisms of relationship be-
tween PLR and tumor recurrence, it is hypothesized that
patients with elevated PLR have a high percentage of
platelet which can secrete cytokines to stimulate angio-
genesis and tumor progression and low percentage of
lymphocytes which play a vital role in antitumor




n Tumor-free survival rates (%) P value
1 year 3 years 5 years
Tumor number
>3 91 30.3 20.0 16.6
0.000
≤3 252 74.0 61.4 60.7
Maximal tumor size (cm)
≤5 233 71.9 62.1 61.2
0.0005 to 8 54 56.4 42.1 36.9
>8 56 27.3 11.8 11.8
Total tumor size (cm)
≤5 154 81.8 73.0 73.0
0.0005 to 8 54 71.9 53.3 53.3
>8 135 36.0 23.0 19.9
Macro-vascular invasion
Yes 101 38.9 18.0 18.0
0.000
No 242 71.9 63.5 61.9
Micro-vascular invasion
Yes 142 44.4 26.1 24.9
0.000
No 201 74.8 68.0 66.9
Differentiation
Poor 148 56.8 43.5 42.1
0.003Moderate 171 63.8 52.4 51.3
Table 1 Tumor-free survival rates of patients according to
different PLR cut-off values
Cut-off
values
n Tumor-free survival rates (%)a P value
1 year 3 years 5 years
PLR ≥50 258 65.8 vs. 62.2 52.1 vs. 50.2 49.8 vs. 49.4 0.710
PLR ≥100 103 67.8 vs. 49.5 55.9 vs. 38.0 54.3 vs. 38.0 0.003
PLR ≥125 55 66.8 vs. 39.9 54.6 vs. 29.8 53.1 vs. 29.8 0.000
PLR ≥150 33 65.6 vs. 39.3 53.4 vs. 24.7 52.1 vs. 24.7 0.001
PLR ≥200 8 63.5 vs. 42.9 50.8 vs. 42.9 49.6 vs. 42.9 0.380
aTumor-free survival rates in the high vs. low PLR group.
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compared HCC recurrence according to the platelet and
lymphocyte counts. The patients were divided according
to the mean platelet count, those with high (≥100.3*109/L,
n = 182) and low (<100.3*109/L, n = 161) platelet groups.
The 1-, 3-, and 5-year tumor-free survival rates were
68.8%, 55.7%, and 54.6% in the low platelet group, respect-
ively, comparable with 56.7%, 46.1%, and 44.5% in the high
platelet group, respectively (P = 0.079, Table 5). For the
lymphocyte count, patients were also divided according to
the mean lymphocyte count. We found that the 1-, 3-, and
5-year tumor-free survival rates were 56.4%, 49.1%, and
47.4%, respectively, in the high lymphocyte group
(≥1.1*109/L, n = 130), similar with 69.4%, 54.2%, and
53.2%, respectively, in the low lymphocyte group
(<1.1*109/L, n = 213) (P = 0.168, Table 5).Well 24 95.8 81.2 81.2
AFP level (ng/ml)
≥200 178 46.9 33.5 31.4
0.000
<200 165 80.4 70.6 70.6
Milan criteria
Yes 144 85.7 76.7 76.7
0.000
No 199 45.0 30.5 28.1Discussion
Since the induction of Milan criteria by Mazzaferro
et al. in 1996, excellent clinical outcome after LT was
achieved for HCC patients within Milan criteria [2,20].
In the following decades, the selection criteria were ex-
panded properly without sacrificing clinical outcomesTable 2 Comparison of clinical characteristics between
PLR ≥125 and PLR <125 groups
Variables PLR P value
<125 (n = 288) ≥125 (n = 55)
Age (years) 49.6 ± 8.6 48.5 ± 11.1 0.480
Gender (male) 260 (90.3%) 48 (87.3%) 0.500
MELD score 13.0 ± 6.0 12.7 ± 6.5 0.755
Types of LT
LDLT 35 (12.2%) 6 (10.9%) 0.794
DDLT 253 (87.8%) 49 (89.1%)
HBV infection 270 (93.8%) 50 (90.9%) 0.390
Pre-LT treatment
Surgical resection 43 (17.1%) 9 (9.8%) 0.786
Interventional therapy 139 (48.3%) 31 (56.4%) 0.271
UCSF criteria
Yes 166 84.3 75.6 75.6
0.000
No 177 41.5 26.2 23.6
Hangzhou criteria
Yes 193 83.3 74.2 74.2
0.000
No 150 35.1 20.0 17.3[5,6]. But most of current selection criteria are based
solely on pre-transplant radiological imaging, with no
consideration of the tumor biological behavior. As a re-
sult, nearly 15% ~ 20% recurrence rates of HCC after LT
are reported in patients who fulfill the Milan or UCSF
criteria [21,22].
On the other hand, pre-transplant radiological imaging
is reported to be inaccurate [7]. In most cases, pre-
transplant radiological imaging always underestimates
Table 4 Relationship between PLR value and tumor-related
characteristics
Variables PLR P value
<125 (n = 288) ≥125 (n = 55)
Tumor number >3 69 (24.0%) 22 (40.0%) 0.014
Largest tumor size (cm)
≤5 214 (74.3%) 19 (34.5%)
0.0005 to 8 43 (14.9%) 11 (20.0%)
>8 31 (10.8%) 25 (45.5%)
Total tumor size (cm)
≤5 144 (50.0%) 10 (18.2%)
0.0005 to 8 46 (16.0%) 8 (14.5%)
>8 98 (34.0%) 37 (67.3%)
Macro-vascular invasion 78 (27.1%) 23 (41.8%) 0.028
Micro-vascular invasion 109 (37.8%) 33 (60.0%) 0.002
Tumor differentiation
Poor 124 (43.1%) 24 (43.6%)
0.246Moderate 141 (49.0%) 30 (54.5%)
Well 23 (8.0%) 1 (1.8%)
AFP ≥200 ng/ml 136 (47.2%) 32 (58.2%) 0.147
Within Milan criteria 135 (46.9%) 9 (16.4%) 0.000
Within UCSF criteria 156 (54.2%) 10 (18.2%) 0.000
Within Hangzhou criteria 177 (61.5%) 16 (29.1%) 0.000
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small tumor lesions. Simultaneously, radiological exam-
ination cannot evaluate the tumor differentiation and
micro-vascular invasion which are strongly associated
with an increased risk of tumor recurrence after LT
[8-10]. Despite being within Milan or UCSF criteria,
patients with these characteristics will likely response
poorly to LT.
In recently years, accumulative evidences have demon-
strated that increased systemic inflammation is related
to poor prognosis of various kinds of cancers including
colorectal cancer, pancreatic cancer, and prostate cancerTable 5 Comparison of tumor-free survival according to
platelet and lymphocyte counts independently
Groups n Tumor-free survival rates (%) P value
1 year 3 years 5 years
Platelet count
High (≥100.3*109/L) 182 56.7 46.1 44.5 0.079
Low (<100.3*109/L) 161 68.8 55.7 54.6
Lymphocyte count
High (≥1.1*109/L) 130 56.4 49.1 47.4 0.168
Low (<1.1*109/L) 213 69.4 54.2 53.2[23-25]. PLR is a simple marker of systemic inflamma-
tion and can be obtained easily from routine blood cell
testing. In this study, we identified that PLR ≥125
showed most significant correlation with tumor recur-
rence. Furthermore, we compared the clinical back-
ground and tumor-related characteristics between PLR
≥125 and <125 groups; we found that PLR ≥125 was as-
sociated with high proportion of multiple tumors, large
tumor size, and micro- and macro-vascular invasion,
and PLR ≥125 was prone to be beyond Milan, UCSF,
and Hangzhou criteria. But we failed to find correlations
of PLR with tumor histological differentiation and AFP
levels. The association of PLR- and tumor-related char-
acteristics was explored in previous studies. Kwon et al.
showed that patients with higher PLR showed a higher
likelihood of positive lymph node in colorectal cancer
[26]. In cervical cancer, increased PLR was related to
bigger tumor size and lymph node metastasis [27]. Azab
et al. reported that increased PLR predicted a higher
rate of lymph node involvement, higher rate of metasta-
sis, and higher American Joint Committee on Cancer
(AJCC) staging in breast cancer patients [28]. To our
knowledge, it is the first study to investigate the relation-
ship between PLR- and HCC-related characteristics,
and our finding indicated elevated PLR implying high
possibility of advanced tumor stage and aggressive tumor
phenotype.
The molecular mechanisms involved in the relation-
ship between PLR and tumor recurrence still remains
unclear; one explanation is that patients with elevated
PLR have a high percentage of platelets and low percent-
age of lymphocytes. The platelets can secret vascular
endothelial growth factor (VEGF) which can cause
angiogenesis and tumor progression [29]. The low per-
centage of lymphocytes indicated impaired host im-
munological response to malignancy [30]. But our
results did not support this explanation, we failed to find
differences of tumor-free survival between high and low
platelet count groups or between high and low lympho-
cyte count groups. Recent study indicated that tumor
microenvironment maybe involved in the association of
systematic inflammation with tumor recurrence [31];
however, the detailed mechanisms are unclear and need
further study.
Conclusions
Our study identified that elevated pre-transplant PLR
was associated with advanced tumor stage and aggres-
sive tumor phenotype, and pre-transplant PLR can be
used as a prognostic factor for post-transplant tumor
recurrence.
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